Share-based Payment Arrangement, Expense of IDEAYA Biosciences, Inc. from 31 Dec 2017 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
IDEAYA Biosciences, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2017 to 31 Dec 2025.
  • IDEAYA Biosciences, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $11,793,000, a 24% increase year-over-year.
  • IDEAYA Biosciences, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $46,115,000, a 33% increase year-over-year.
  • IDEAYA Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2025 was $46,115,000, a 33% increase from 2024.
  • IDEAYA Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $34,746,000, a 88% increase from 2023.
  • IDEAYA Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $18,489,000, a 59% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

IDEAYA Biosciences, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $46,115,000 $11,793,000 +$2,308,000 +24% 01 Oct 2025 31 Dec 2025 10-K 17 Feb 2026 2025 FY
Q3 2025 $43,807,000 $12,217,000 +$3,002,000 +33% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $40,805,000 $11,868,000 +$2,134,000 +22% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $38,671,000 $10,237,000 +$3,925,000 +62% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $34,746,000 $9,485,000 +$4,687,000 +98% 01 Oct 2024 31 Dec 2024 10-K 17 Feb 2026 2025 FY
Q3 2024 $30,059,000 $9,215,000 +$3,914,000 +74% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $26,145,000 $9,734,000 +$5,003,000 +106% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $21,142,000 $6,312,000 +$2,653,000 +73% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $18,489,000 $4,798,000 +$1,822,000 +61% 01 Oct 2023 31 Dec 2023 10-K 17 Feb 2026 2025 FY
Q3 2023 $16,667,000 $5,301,000 +$2,297,000 +76% 01 Jul 2023 30 Sep 2023 10-Q 04 Nov 2024 2024 Q3
Q2 2023 $14,370,000 $4,731,000 +$1,687,000 +55% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $12,683,000 $3,659,000 +$1,054,000 +40% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $11,629,000 $2,976,000 +$912,000 +44% 01 Oct 2022 31 Dec 2022 10-K 18 Feb 2025 2024 FY
Q3 2022 $10,717,000 $3,004,000 +$807,000 +37% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $9,910,000 $3,044,000 +$986,000 +48% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $8,924,000 $2,605,000 +$687,000 +36% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $8,237,000 $2,064,000 +$1,018,000 +97% 01 Oct 2021 31 Dec 2021 10-K 20 Feb 2024 2023 FY
Q3 2021 $7,219,000 $2,197,000 +$1,216,000 +124% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $6,003,000 $2,058,000 +$1,234,000 +150% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $4,769,000 $1,918,000 +$1,160,000 +153% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $3,609,000 $1,046,000 +$327,000 +45% 01 Oct 2020 31 Dec 2020 10-K 07 Mar 2023 2022 FY
Q3 2020 $3,282,000 $981,000 +$463,000 +89% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $2,819,000 $824,000 +$276,000 +50% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q1 2020 $2,543,000 $758,000 +$375,000 +98% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $2,168,000 $719,000 01 Oct 2019 31 Dec 2019 10-K 18 Mar 2022 2021 FY
Q3 2019 $518,000 +$231,000 +80% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $548,000 +$322,000 +142% 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020 2020 Q2
Q1 2019 $383,000 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020 2020 Q1
Q3 2018 $287,000 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019 2019 Q3
Q2 2018 $226,000 01 Apr 2018 30 Jun 2018 10-Q 12 Aug 2019 2019 Q2

IDEAYA Biosciences, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $46,115,000 +$11,369,000 +33% 01 Jan 2025 31 Dec 2025 10-K 17 Feb 2026 2025 FY
2024 $34,746,000 +$16,257,000 +88% 01 Jan 2024 31 Dec 2024 10-K 17 Feb 2026 2025 FY
2023 $18,489,000 +$6,860,000 +59% 01 Jan 2023 31 Dec 2023 10-K 17 Feb 2026 2025 FY
2022 $11,629,000 +$3,392,000 +41% 01 Jan 2022 31 Dec 2022 10-K 18 Feb 2025 2024 FY
2021 $8,237,000 +$4,628,000 +128% 01 Jan 2021 31 Dec 2021 10-K 20 Feb 2024 2023 FY
2020 $3,609,000 +$1,441,000 +66% 01 Jan 2020 31 Dec 2020 10-K 07 Mar 2023 2022 FY
2019 $2,168,000 +$1,218,000 +128% 01 Jan 2019 31 Dec 2019 10-K 18 Mar 2022 2021 FY
2018 $950,000 +$814,000 +599% 01 Jan 2018 31 Dec 2018 10-K 23 Mar 2021 2020 FY
2017 $136,000 01 Jan 2017 31 Dec 2017 10-K 24 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.